No products in the cart.
Pre-made Timolumab benchmark antibody ( Whole mAb, anti-AOC3 therapeutic antibody, Anti-HPAO/SSAO/VAP-1/VAP1 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-577
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Timolumab biosimilar, Whole mAb, Anti-AOC3 Antibody: Anti-HPAO/SSAO/VAP-1/VAP1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
TECHNOLOGY. DESCRIPTION. Timolumab (BTT-1023; SI-3106; SI-636) is a fully human, monoclonal, anti-vascular adhesion protein- 1 (VAP-1) antibody which works by blocking the adhesion function of VAP-1 which diminishes. leucocyte entry to sites of inflammation.
| Products Name (INN Index) | Pre-Made Timolumab biosimilar, Whole mAb, Anti-AOC3 Antibody: Anti-HPAO/SSAO/VAP-1/VAP1 therapeutic antibody |
|---|---|
| INN Name | Timolumab |
| Target | AOC3 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2015 |
| Year Recommended | 2016 |
| Companies | Acorda Therapeutics,Biotie Therapies Corp.,Seikagaku Corporation |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Inflammation,Plaque psoriasis,Rheumatoid arthritis,Primary sclerosing cholangitis |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | AOC3 |
| Package |
Previous slide
Next slide
